{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:43:30Z","timestamp":1783100610506,"version":"3.54.6"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1053\/j.seminhematol.2018.07.006","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T02:47:38Z","timestamp":1551235658000},"page":"26-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH"],"prefix":"10.1053","volume":"57","author":[{"given":"Han","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2018.07.006_bib0001","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0002","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0003","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0004","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2018.07.006_bib0005","article-title":"Flow cytometric immunophenotyping is sensitive for the early diagnosis of de novo Aggressive Natural Killer Cell Leukemia (ANKL): a multicenter retrospective analysis","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0006","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/asheducation-2015.1.177","article-title":"Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis","volume":"1","author":"Allen","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0007","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/asheducation-2015.1.190","article-title":"Treatment of hemophagocytic lymphohistiocytosis in adults","volume":"1","author":"La Ros\u00b4ee","year":"2015","journal-title":"Hematol Am SocHematol Educ Program"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/BOR.0b013e32834dd37e","article-title":"Not all hemophagocytes are created equally: appreciating the heterogeneity of the hemophagocytic syndromes","volume":"24","author":"Canna","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0009","article-title":"Correlation and cluster analysis of immunomodulatory drugs based on cytokine profiles","volume":"25","author":"Wallner","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0010","article-title":"Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients","volume":"4","author":"O'Gorman","year":"2017","journal-title":"J Autoimmun"},{"issue":"24","key":"10.1053\/j.seminhematol.2018.07.006_bib0011","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0012","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0013","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.fct.2016.08.018","article-title":"Inhibition of the JAK\/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity","volume":"96","author":"Shaker","year":"2016","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"10.1053\/j.seminhematol.2018.07.006_bib0014","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.24971","article-title":"Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience","volume":"93","author":"Slostad","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0015","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report","author":"Sin","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0016","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1053\/j.seminhematol.2018.07.006_bib0017","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.seminhematol.2018.07.006_bib0018","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","article-title":"Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis","volume":"1","author":"Broglie","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1053\/j.seminhematol.2018.07.006_bib0019","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002","article-title":"Macrophage activation syndrome and cytokine-directed therapies","volume":"28","author":"Schulert","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196318300155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196318300155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:26:07Z","timestamp":1758522367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196318300155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0037196318300155"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.07.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2018.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}